期刊文献+

普萘洛尔治疗并发溃疡婴幼儿血管瘤11例的临床观察 被引量:1

Clinical observation of propranolol for the treatment of infantile hemangioma with ulceration
原文传递
导出
摘要 目的评价普萘洛尔治疗婴幼儿并发溃疡血管瘤临床疗效和安全性。方法 11例并发溃疡的婴幼儿血管瘤患者口服普萘洛尔,起始剂量每天1.0mg/kg,12小时给药一次;每天递增0.5mg,至第3天以后维持每天2.0mg/kg,连续服用3~5个月。溃疡创面从治疗开始每日换药一次。每周复诊,动态观察和记录血管瘤溃疡创面情况以及瘤体大小、质地、颜色的变化。结果 11例患儿随访7~10月,8例瘤体缩小75%~100%,3例缩小50%~75%。血管瘤溃疡创面均在2~3周内愈合。发现心率减慢、腹泻、溢奶、睡眠改变等不良反应,均未需做特殊处理,2周内好转,未发现严重不良反应。结论口服小剂量普萘洛尔治疗婴幼儿并发溃疡血管瘤,能使溃疡创面在短期内愈合,并能使血管瘤体明显缩小,不良反应轻微。 bjective To evaluate the efficacy and safety of propranolol for the treatment of infantile hemangioma with ulceration.Method Oral propranolol was administered to 11 infants with hemangioma complicated by ulceration at a initial dose of 1.0 mg/kg of body weight per day. Medication was given every 12 hours, increasing 0.5 every day, to 2.0 mg/kg per day and 3 days latet the propranolol treatment was contituted for 3-5 months. Ulcers from treatment started a daily dressing change. Weekly visits, dynamic observation and recording hemangioma ulcers and tumor size, texture and color changes were done. Results Among the 17 patients treated,the follow-up time was 5-10 months. Hemangioma body reduced 75%-100% in 8 cases, 50%-75% in 3 cases. Hemangioma ulcers were all healed in 2-3 weeks. The main adverse effects were bradycardia, diarrhoea, spilled milk, changes in sleep, which resolved without special handling within two weeks.No serious adverse effect was observed. Conclusions Oral small dosage propranolol for infantile hemangioma complicated ulcers can make the ulcer heal in a short term, and can significantly reduce the hemangioma body, and the adverse reactions were minimal.
出处 《中华损伤与修复杂志(电子版)》 CAS 2011年第5期53-55,68,共4页 Chinese Journal of Injury Repair and Wound Healing(Electronic Edition)
关键词 血管瘤 皮肤溃疡 普萘洛尔 婴儿 Hemangioma Skin ulcer Propranolol Infant
  • 相关文献

参考文献4

二级参考文献48

  • 1Metry D. Update on hemangiomas of infancy. Curt Opin Pediatr, 2004, 16:373-377.
  • 2Bennett ML, Fleiseher Jr AB, Chamlin SL, et al. Oral eortieosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol, 2001, 137 : 1208-1213.
  • 3Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alpha 2a therapy for life threatening hemangiomas of infancy. N Engl J Med, 1992, 326 : 1456-1463.
  • 4Enjolras O, Breviere GM, Roger G, et al. Vincristine treatment for function-and life-threatening infantile hemangioma. Arch Pediatr, 2004, 11:99-107.
  • 5Leaute-Labreze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med, 2008, 358:2649-2651.
  • 6Waner M, Suen JY. A classification of congenital vascular lesions//Waner M, Suen JY. Hemangiomas and vascular malformations of the head and neck. New York: Wiley-Liss, 1999 : 1-12.
  • 7Achauer BM, Chang C J, Vander Kam VM. Management of hemangioma of infancy: review of 245 patients. Plast Reconstr Surg, 1997, 99 : 1301-1308.
  • 8Siegfried EC, Keenan WJ, Al-Jureidini S. More on propranolol for hemangiomas of infancy. N Engl J Med, 2008, 359:2846.
  • 9Buekmiller L, Dyamenahalli U, Richter GT. Propranolol for airway hemangiomas : ease report of novel treatment. Laryngoscope, 2009, 119:2051-2054.
  • 10Gottschling S, Schneider G, Meyer S, et al. Two infants with life- threatening diffuse neonatal hemangiomatosis treated with cyclophosphamide. Pediatr Blood Cancer, 2006, 46:239-224.

共引文献274

同被引文献6

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部